<p>Neurogene Inc.（纳斯达克代码：NGNE - 获取免费报告）在覆盖该股票的七家评级公司中获得了 “持有” 的共识评级，Marketbeat 报道。一位股票研究分析师对该股票给予了卖出建议，两位给予了持有建议，四位给予了买入建议。在过去一年中，给予该股票评级的经纪人平均目标价为 42.50 美元。</p>
<ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
<p>NGNE 一直是多份研究分析师报告的主题。HC Wainwright 在 1 月 13 日的报告中重申了 “买入” 评级，并将 Neurogene 的目标价设定为 70.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Neurogene 的 “卖出（d-）” 评级。最后，华尔街禅在 12 月 13 日的研究报告中将 Neurogene 的评级从 “持有” 下调至 “卖出”。</p>
<p><strong>获取我们对 Neurogene 的最新股票分析</strong></p>
<h2>机构投资者对 Neurogene 的看法</h2>
<p>一些机构投资者和对冲基金最近调整了对该股票的持有。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Neurogene 的持股增加了 17.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 6,983 股该公司的股票，价值 82,000 美元，此前在上个季度购买了 1,059 股。Jennison Associates LLC 在第二季度将其在 Neurogene 的持股增加了 55.0%。Jennison Associates LLC 目前拥有 167,563 股该公司的股票，价值 2,505,000 美元，此前在此期间购买了 59,479 股。PNC Financial Services Group Inc. 在第二季度将其在 Neurogene 的持股增加了 43.6%。PNC Financial Services Group Inc. 目前拥有 4,055 股该公司的股票，价值 61,000 美元，此前在上个季度购买了 1,232 股。施罗德投资管理集团在第二季度获得了对 Neurogene 的新头寸，价值约为 451,000 美元。最后，美国银行（Bank of America Corp DE）在第二季度将其在 Neurogene 的持股增加了 81.6%。美国银行（Bank of America Corp DE）目前拥有 95,401 股该公司的股票，价值 1,426,000 美元，此前在此期间收购了 42,880 股。52.37% 的股票由机构投资者和对冲基金持有。</p>
<h2>Neurogene 价格表现</h2>
<p>NASDAQ:NGNE 的股票周一开盘价为 17.55 美元。该股票的市值为 2.7185 亿美元，市盈率为-4.27，贝塔值为 1.60。Neurogene 的 12 个月低点为 6.88 美元，12 个月高点为 37.27 美元。该股票的 50 日移动平均价格为 20.76 美元，200 日移动平均价格为 22.12 美元。</p>
<p>Neurogene（纳斯达克代码：NGNE - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为（0.99 美元），超出分析师的共识预期（1.26 美元）0.27 美元。平均而言，卖方分析师预计 Neurogene 本年度将发布-4.27 的每股收益。</p>
<h2>关于 Neurogene</h2>
<p>（获取免费报告）</p>
<p>Neurogene, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见神经疾病的基因疗法。该公司的主要平台采用腺相关病毒（AAV）载体，旨在将功能性疾病基因的拷贝直接传递到中枢神经系统。Neurogene 的产品线专注于遗传性溶酶体储存疾病，包括针对 GM1 和 GM2 神经节苷脂症的研究项目，以及针对其他单基因神经退行性疾病的额外前临床努力。</p>
<p>Neurogene 的专有 AAV9 基于递送系统经过工程设计，能够跨越血脑屏障，旨在提供在受影响组织中的持久基因表达。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Neurogene 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>行政命令 14330：特朗普最大的举措</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Neurogene 吗？</h2>
<p>在您考虑 Neurogene 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Neurogene 并不在名单上。</p>
<p>虽然 Neurogene 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

NGNE

<p>Neurogene Inc.（纳斯达克代码：NGNE）获得了分析师的 “持有” 共识评级，其中包括一项卖出、两项持有和四项买入建议。平均目标价格为 42.50 美元。机构投资者增加了持股比例，持有该股票的比例为 52.37%。该股票开盘价为 17.55 美元，市值为 2.7185 亿美元，市盈率为-4.27。Neurogene 专注于罕见神经疾病的基因疗法，重点关注遗传性溶酶体储存疾病</p>

<p>Neurogene Inc. (NASDAQ:NGNE - Get Free Report) has received a consensus rating of &#34;Hold&#34; from the seven ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $42.50.</p>
<div class="lb-trans"><p>Neurogene Inc.（纳斯达克代码：NGNE - 获取免费报告）在覆盖该股票的七家评级公司中获得了 “持有” 的共识评级，Marketbeat 报道。一位股票研究分析师对该股票给予了卖出建议，两位给予了持有建议，四位给予了买入建议。在过去一年中，给予该股票评级的经纪人平均目标价为 42.50 美元。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：这家生物科技公司还有希望吗？</li>
</ul>
</div><p>NGNE has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $70.00 target price on shares of Neurogene in a report on Tuesday, January 13th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Neurogene from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, December 13th.</p>
<div class="lb-trans"><p>NGNE 一直是多份研究分析师报告的主题。HC Wainwright 在 1 月 13 日的报告中重申了 “买入” 评级，并将 Neurogene 的目标价设定为 70.00 美元。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Neurogene 的 “卖出（d-）” 评级。最后，华尔街禅在 12 月 13 日的研究报告中将 Neurogene 的评级从 “持有” 下调至 “卖出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on Neurogene</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Neurogene 的最新股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Neurogene</h2>
<div class="lb-trans"><h2>机构投资者对 Neurogene 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Jennison Associates LLC raised its holdings in Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company's stock worth $2,505,000 after buying an additional 59,479 shares during the period. PNC Financial Services Group Inc. lifted its stake in Neurogene by 43.6% during the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock valued at $61,000 after buying an additional 1,232 shares in the last quarter. Schroder Investment Management Group acquired a new position in shares of Neurogene in the second quarter worth about $451,000. Finally, Bank of America Corp DE raised its holdings in shares of Neurogene by 81.6% during the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock valued at $1,426,000 after acquiring an additional 42,880 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对该股票的持有。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 Neurogene 的持股增加了 17.9%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 6,983 股该公司的股票，价值 82,000 美元，此前在上个季度购买了 1,059 股。Jennison Associates LLC 在第二季度将其在 Neurogene 的持股增加了 55.0%。Jennison Associates LLC 目前拥有 167,563 股该公司的股票，价值 2,505,000 美元，此前在此期间购买了 59,479 股。PNC Financial Services Group Inc. 在第二季度将其在 Neurogene 的持股增加了 43.6%。PNC Financial Services Group Inc. 目前拥有 4,055 股该公司的股票，价值 61,000 美元，此前在上个季度购买了 1,232 股。施罗德投资管理集团在第二季度获得了对 Neurogene 的新头寸，价值约为 451,000 美元。最后，美国银行（Bank of America Corp DE）在第二季度将其在 Neurogene 的持股增加了 81.6%。美国银行（Bank of America Corp DE）目前拥有 95,401 股该公司的股票，价值 1,426,000 美元，此前在此期间收购了 42,880 股。52.37% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Neurogene Price Performance</h2>
<div class="lb-trans"><h2>Neurogene 价格表现</h2>
</div><p>Shares of NASDAQ:NGNE opened at $17.55 on Monday. The stock has a market cap of $271.85 million, a price-to-earnings ratio of -4.27 and a beta of 1.60. Neurogene has a 12 month low of $6.88 and a 12 month high of $37.27. The stock's 50 day moving average price is $20.76 and its 200 day moving average price is $22.12.</p>
<div class="lb-trans"><p>NASDAQ:NGNE 的股票周一开盘价为 17.55 美元。该股票的市值为 2.7185 亿美元，市盈率为-4.27，贝塔值为 1.60。Neurogene 的 12 个月低点为 6.88 美元，12 个月高点为 37.27 美元。该股票的 50 日移动平均价格为 20.76 美元，200 日移动平均价格为 22.12 美元。</p>
</div><p>Neurogene (NASDAQ:NGNE - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.99) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.27. On average, sell-side analysts expect that Neurogene will post -4.27 EPS for the current year.</p>
<div class="lb-trans"><p>Neurogene（纳斯达克代码：NGNE - 获取免费报告）最近于 11 月 13 日发布了季度财报。该公司报告每股收益（EPS）为（0.99 美元），超出分析师的共识预期（1.26 美元）0.27 美元。平均而言，卖方分析师预计 Neurogene 本年度将发布-4.27 的每股收益。</p>
</div><h2>About Neurogene</h2>
<div class="lb-trans"><h2>关于 Neurogene</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.</p>
<div class="lb-trans"><p>Neurogene, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见神经疾病的基因疗法。该公司的主要平台采用腺相关病毒（AAV）载体，旨在将功能性疾病基因的拷贝直接传递到中枢神经系统。Neurogene 的产品线专注于遗传性溶酶体储存疾病，包括针对 GM1 和 GM2 神经节苷脂症的研究项目，以及针对其他单基因神经退行性疾病的额外前临床努力。</p>
</div><p>Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.</p>
<div class="lb-trans"><p>Neurogene 的专有 AAV9 基于递送系统经过工程设计，能够跨越血脑屏障，旨在提供在受影响组织中的持久基因表达。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Neurogene</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Neurogene 更好</li>
<li>Elon 将 SpaceX 上市！$100 的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>用这四个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>行政命令 14330：特朗普最大的举措</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NGNE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neurogene Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Neurogene 吗？</h2>
</div><p>Before you consider Neurogene, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Neurogene 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Neurogene 并不在名单上。</p>
</div><p>While Neurogene currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Neurogene 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Neurogene Inc.（NASDAQ:NGNE）被分析师平均建议为 “持有”